Norfolk research company plans clinical trials using medical marijuana
Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions.
Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer. The new venture potentially opens the door to significantly expanding national research being done on the medical benefits of cannabis. Read the full story here.
Stories you may be interested in
Customize Your Patient Notes with Arfinn Med
Joining the text messaging update, the Arfinn Med portal now presents the ability to create note taking templates. This innovative addition will allow physicians to streamline the data and information that they are collecting from patients, resulting in their cases staying aligned and concise. Additionally, through this function, physicians will be able to pick and…
Read More 
$2.7 million awarded for medical marijuana research in Colorado
The state has awarded $2.7 million for research into how medical marijuana could replace opioids to ease chronic spinal pain — and how it might treat irritability in children and adolescents with autism. Read the full story here.
Read More 
THC vs. CBD: What You Need to Know
With the rising demand of natural medicines, medical marijuana compounds THC and CBD are starting to make a name for themselves more than ever before. These two compounds have a wide range of health benefits, making it understandable why patients and physicians would be interested in this alternative treatment option. Although these two compounds are…
Read More 
REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals
Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More 
Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says
Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020. Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber…
Read More 
World Cancer Day – Shine a Light on the World
In 2018, it was estimated that 1,735,350 new cancer cases would be diagnosed in the United States and 609,640 individuals would pass from the disease [Cancer.gov]. We cannot sit by and ignore this life altering disease, which is why World Cancer Day, recognized on Feb. 4, is such an important awareness campaign to the Arfinn…
Read More